Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells
MDM2 and MDM4 are major negative regulators of tumor suppressor p53. Beyond regulating p53, MDM2 possesses p53-independent activity in promoting cell cycle progression and tumorigenesis via its RING domain ubiquitin E3 ligase activity. MDM2 and MDM4 form heterodimer polyubiquitin E3 ligases via thei...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/30/1/186 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841549090430648320 |
|---|---|
| author | Rati Lama Joseph M. Fose Diana Martín Inés G. Muñoz Eunice S. Wang Pamela J. Sung Sherry R. Chemler Xinjiang Wang |
| author_facet | Rati Lama Joseph M. Fose Diana Martín Inés G. Muñoz Eunice S. Wang Pamela J. Sung Sherry R. Chemler Xinjiang Wang |
| author_sort | Rati Lama |
| collection | DOAJ |
| description | MDM2 and MDM4 are major negative regulators of tumor suppressor p53. Beyond regulating p53, MDM2 possesses p53-independent activity in promoting cell cycle progression and tumorigenesis via its RING domain ubiquitin E3 ligase activity. MDM2 and MDM4 form heterodimer polyubiquitin E3 ligases via their RING domain interaction. Inhibitors disrupting p53 interaction with MDM2/MDM4 are in clinical trials in patients bearing wild-type p53 cancers. However, these inhibitors are not designed to work for p53-null/mutant cancer cells. Owing to the importance of the E3 ligase of MDM2 in its p53-independent oncogenic activity, inhibitors targeting the E3 ligase activity of MDM2-MDM4 are desirable for p53-mutant cancer cells. Here, we report the development of such inhibitors with pro-apoptotic activity in p53-null leukemic cells. Among analogues of MDM2-MDM4 E3 ligase inhibitors, we initially identified MMRi36 as a potent pro-apoptotic compound in p53-null leukemic cells with acquired drug resistance. MMRi36 acts as an activator of MDM2-MDM4 E3 ligase by stabilizing MDM2-MDM4 heterodimers and promotes MDM2/MDM4 degradation in cells. Interestingly, replacement of the sulfur in 1,3,4-thiadiazole MMRi36 with a carbon led to identification of pyrazole MMRi36C that dissociates the MDM2-MDM4 RING heterodimers, inhibits the E3 ligase activity of the complex, and induces p53 protein accumulation, but retains the p53-independent pro-apoptotic activity. A brief SAR study identified a fluorine derivative of MMRi36C with improved pro-apoptotic activity. This study discovered a novel class of compound that targets MDM2-MDM4 ubiquitin E3 ligase activity for apoptosis induction in p53-mutant cancer cells. |
| format | Article |
| id | doaj-art-a7689d00dbc64fc3ae981c1fb00f516b |
| institution | Kabale University |
| issn | 1420-3049 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj-art-a7689d00dbc64fc3ae981c1fb00f516b2025-01-10T13:19:08ZengMDPI AGMolecules1420-30492025-01-0130118610.3390/molecules30010186Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic CellsRati Lama0Joseph M. Fose1Diana Martín2Inés G. Muñoz3Eunice S. Wang4Pamela J. Sung5Sherry R. Chemler6Xinjiang Wang7Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USADepartment of Chemistry, University at Buffalo, State University of New York, Buffalo, NY 14260, USAStructural Biology Programme, Spanish National Cancer Research Centre (CNIO), 28009 Madrid, SpainStructural Biology Programme, Spanish National Cancer Research Centre (CNIO), 28009 Madrid, SpainDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USADepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USADepartment of Chemistry, University at Buffalo, State University of New York, Buffalo, NY 14260, USADepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USAMDM2 and MDM4 are major negative regulators of tumor suppressor p53. Beyond regulating p53, MDM2 possesses p53-independent activity in promoting cell cycle progression and tumorigenesis via its RING domain ubiquitin E3 ligase activity. MDM2 and MDM4 form heterodimer polyubiquitin E3 ligases via their RING domain interaction. Inhibitors disrupting p53 interaction with MDM2/MDM4 are in clinical trials in patients bearing wild-type p53 cancers. However, these inhibitors are not designed to work for p53-null/mutant cancer cells. Owing to the importance of the E3 ligase of MDM2 in its p53-independent oncogenic activity, inhibitors targeting the E3 ligase activity of MDM2-MDM4 are desirable for p53-mutant cancer cells. Here, we report the development of such inhibitors with pro-apoptotic activity in p53-null leukemic cells. Among analogues of MDM2-MDM4 E3 ligase inhibitors, we initially identified MMRi36 as a potent pro-apoptotic compound in p53-null leukemic cells with acquired drug resistance. MMRi36 acts as an activator of MDM2-MDM4 E3 ligase by stabilizing MDM2-MDM4 heterodimers and promotes MDM2/MDM4 degradation in cells. Interestingly, replacement of the sulfur in 1,3,4-thiadiazole MMRi36 with a carbon led to identification of pyrazole MMRi36C that dissociates the MDM2-MDM4 RING heterodimers, inhibits the E3 ligase activity of the complex, and induces p53 protein accumulation, but retains the p53-independent pro-apoptotic activity. A brief SAR study identified a fluorine derivative of MMRi36C with improved pro-apoptotic activity. This study discovered a novel class of compound that targets MDM2-MDM4 ubiquitin E3 ligase activity for apoptosis induction in p53-mutant cancer cells.https://www.mdpi.com/1420-3049/30/1/186MMRi36MMRi36CthiadiazoleMDM2-MDM4E3 ligasep53-independent |
| spellingShingle | Rati Lama Joseph M. Fose Diana Martín Inés G. Muñoz Eunice S. Wang Pamela J. Sung Sherry R. Chemler Xinjiang Wang Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells Molecules MMRi36 MMRi36C thiadiazole MDM2-MDM4 E3 ligase p53-independent |
| title | Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells |
| title_full | Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells |
| title_fullStr | Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells |
| title_full_unstemmed | Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells |
| title_short | Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells |
| title_sort | novel inhibitors for mdm2 mdm4 e3 ligase potently induce p53 indepedent apoptosis in drug resistant leukemic cells |
| topic | MMRi36 MMRi36C thiadiazole MDM2-MDM4 E3 ligase p53-independent |
| url | https://www.mdpi.com/1420-3049/30/1/186 |
| work_keys_str_mv | AT ratilama novelinhibitorsformdm2mdm4e3ligasepotentlyinducep53indepedentapoptosisindrugresistantleukemiccells AT josephmfose novelinhibitorsformdm2mdm4e3ligasepotentlyinducep53indepedentapoptosisindrugresistantleukemiccells AT dianamartin novelinhibitorsformdm2mdm4e3ligasepotentlyinducep53indepedentapoptosisindrugresistantleukemiccells AT inesgmunoz novelinhibitorsformdm2mdm4e3ligasepotentlyinducep53indepedentapoptosisindrugresistantleukemiccells AT euniceswang novelinhibitorsformdm2mdm4e3ligasepotentlyinducep53indepedentapoptosisindrugresistantleukemiccells AT pamelajsung novelinhibitorsformdm2mdm4e3ligasepotentlyinducep53indepedentapoptosisindrugresistantleukemiccells AT sherryrchemler novelinhibitorsformdm2mdm4e3ligasepotentlyinducep53indepedentapoptosisindrugresistantleukemiccells AT xinjiangwang novelinhibitorsformdm2mdm4e3ligasepotentlyinducep53indepedentapoptosisindrugresistantleukemiccells |